Humedix signed an agreement with Daejeon’s G2GBIO to cooperate on the development of long-acting injectable drugs, the Kosdaq-listed biopharmaceutical company said Tuesday.
Humedix is acquiring 1.56 percent of Seattle’s Kineta for $2 million in a move to strengthen its contract manufacturing organization (CMO) business.
Humedix made a partnership with Bionote, a company that specializes in developing coronavirus test kits, and obtained the rights to sell the test kits overseas.
Korea JoongAng Daily Sitemap